» Articles » PMID: 10982285

A Comparison of Inpatient and Outpatient ASCT

Overview
Specialty General Surgery
Date 2000 Sep 12
PMID 10982285
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

Outpatient high-dose chemotherapy and autologous stem cell transplantation (ASCT) has been shown to be feasible in terms of physical morbidity and mortality outcomes, but few data exist on the psychosocial impact of delivering such aggressive therapy in this manner. The purpose of this observational study was to compare effects of inpatient (n = 20) and outpatient (n = 21) modes of care on physical status, psychological well-being, quality of life, personal finances and caregiver burden. Most patients were treated according to their preference for inpatient or outpatient care. Those choosing outpatient care were screened for eligibility according to established criteria for ambulatory management. Measures were taken at baseline, then at days 4-6, 12-16 and 30 post ASCT. Results showed that overall, the psychological, physical, social and financial outcomes of the outpatient ASCT group were comparable, to or better than inpatients. Factors that seem to be important for successful outpatient management are previous experience with cancer treatment, a satisfying quality of life, physical well-being, patient's preference for a particular mode of care and physical proximity to the treatment centre. The study results suggest that outpatient ASCT is an efficient, effective and acceptable form of care for motivated patients and caregivers who have the physical and psychological capability and desire to receive cancer treatment in this manner.

Citing Articles

Ambulatory models for autologous stem-cell transplantation: a systematic review of the health impact.

Prieto Del Prado M, Fernandez Aviles F Front Immunol. 2024; 15:1419186.

PMID: 39081323 PMC: 11287121. DOI: 10.3389/fimmu.2024.1419186.


Clinician and administrator perspectives on outpatient administration of ciltacabtagene autoleucel in relapsed or refractory multiple myeloma.

Hansen D, Dhakal B, Hamadani M, Dingli D, Jain T, Huff C Front Immunol. 2024; 15:1405452.

PMID: 38915401 PMC: 11194690. DOI: 10.3389/fimmu.2024.1405452.


Chimeric antigen receptor T-cell therapy: Challenges and framework of outpatient administration.

Gatwood K, Dholaria B, Lucena M, Baer B, Savani B, Oluwole O EJHaem. 2022; 3(Suppl 1):54-60.

PMID: 35844300 PMC: 9176074. DOI: 10.1002/jha2.333.


Hospital and outpatient models for Hematopoietic Stem Cell Transplantation: A systematic review of comparative studies for health outcomes, experience of care and costs.

Gonzalez M, Urizar E, Urtaran-Laresgoiti M, Nuno-Solinis R, Lazaro-Perez E, Vazquez L PLoS One. 2021; 16(8):e0254135.

PMID: 34383780 PMC: 8360565. DOI: 10.1371/journal.pone.0254135.


Multiple Myeloma Outpatient Transplant Program in the Era of Novel Agents: State-of-the-Art.

Martino M, Paviglianiti A, Memoli M, Martinelli G, Cerchione C Front Oncol. 2020; 10:592487.

PMID: 33262948 PMC: 7686536. DOI: 10.3389/fonc.2020.592487.